Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Janux Therapeutics, Inc.NASDAQ: JANX

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses dips below year-ago levels

Q1 FY2026 other income / expenses of $9.85M fell 13.5% year over year, behind the +18.6% change in trailing-twelve-month other income / expenses. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at +121.9% a year.

Context

  • Other income / expenses amounted to 440.4% of revenue in FY2025, up 158.5 pp from a year earlier.
  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -13.5% toward the trailing-twelve-month pace of +18.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.85M-5.8% QoQ
Last fiscal yearDec 2025
$44.04M+47.5% YoY
LTMMar 2026
$42.51M+18.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.5%——
1 year+47.5%——
3-year CAGR+121.9%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
44.04M USD
Year-over-year change
+47.5%
4-year CAGR
+261.8%

Other Income / Expenses vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +18.6% is the 3rd highest of 10, against a peer median of -19.9%.
  • Other income / expenses amounts to 196.7% of revenue for JANX, versus a peer median of 11.6%.
JANX Competitors
Other Income / Expenses for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JANXJanux Therapeutics, Inc.LTM Mar 2026$42.51M USD+18.6%+121.9%196.7%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$25.39M USD-19.9%+114.2%22670.5%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$19.31M USD-36.3%+48.3%—
IMNMImmunome, Inc.LTM Sep 2026$18.04M USD+57.2%+600.5%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$7M USD+6.0%+37.7%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$5.75M USD-2.2%+37.4%16.2%
LEGNLegend Biotech CorporationLTM Sep 2026-$1.9M USD+94.1%—0.1%
IMTXImmatics N.V.LTM Mar 2026-€2.64M EUR-106.2%—7.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$7.37M USD-116.5%—4.7%
STROSutro Biopharma, Inc.LTM Mar 2026-$38.64M USD-613.7%—38.8%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —-19.9%+48.3%11.6%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.